Progyny, Inc. reported a revenue of $324.0 million for the first quarter of 2025, marking a 17% increase from $278.1 million in the same period of the previous year. The growth was primarily driven by a 22% rise in revenue from its fertility benefits solution, which generated $206.4 million, and a 9% increase in revenue from its pharmacy benefits solution, totaling $117.6 million. Despite the revenue growth, the company experienced a decline in net income, which fell to $15.1 million from $16.9 million year-over-year, attributed to increased operating expenses and a higher provision for income taxes.
The company's total operating expenses rose to $51.6 million, up from $43.9 million in the prior year, largely due to increased personnel costs and stock-based compensation. The gross profit for the quarter was $75.8 million, resulting in a gross margin of 23.4%, an improvement from 22.4% in the previous year. The increase in gross margin reflects ongoing efficiencies in the delivery of care management services. Additionally, Progyny's cash and cash equivalents decreased to $109.2 million from $162.3 million at the end of 2024, while marketable securities increased significantly to $146.9 million.
In terms of operational metrics, Progyny expanded its client base to 532 employers, covering approximately 6.7 million lives, up from 473 clients and 6.5 million lives at the end of 2024. The company has retained a high level of client satisfaction, evidenced by a Net Promoter Score of +79 for its fertility benefits solution. The company also completed the acquisition of Benefit Bump LLC, a parental leave benefits navigation program, for $10.5 million, enhancing its offerings in family-building solutions.
Looking ahead, Progyny anticipates continued growth driven by its strategic focus on expanding its client base and enhancing service offerings. The company plans to invest in sales and marketing to increase awareness of its fertility solutions among potential clients. However, it also faces challenges, including competition in the fertility benefits market and potential impacts from economic conditions and regulatory changes. The company remains committed to maintaining its market position and improving its service delivery to meet the evolving needs of its clients and members.
About Progyny, Inc.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.